子類別 期刊論文 [327/330] 圖書 [1/1] 會議論文/會議摘要 [115/179] 鄰近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群統計 近3年內發表的文件:74(14.51%) 含全文筆數:443(86.86%) 文件下載次數統計 下載大於0次:443(100.00%) 下載大於100次:426(96.16%) 檔案下載總次數:178043(3.32%) 最後更新時間: 2024-12-01 03:12 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目251-275 / 510. (共21頁) << < 6 7 8 9 10 11 12 13 14 15 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2016-10	Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor	Cancer Research and Treatment. 2016 Oct;48(4):1155-1166.
2016-10	BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia	Molecular Cancer Therapeutics. 2016 Oct;15(10):2323-2333.
2016-10	Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-b	Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):259.
2016-10	Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with ge	Oncology Research and Treatment. 2016 Oct;39(Suppl. 3):260.
2016-10	Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 622PD.
2016-10	Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 693P.
2016-10	CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma	Annals of Oncology. 2016 Oct;27(Suppl. 6):Meeting Abstract 933P.
2016-09	The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer	Oncotarget. 2016 Sep;7(38):61136-61151.
2016-09	Effects of nanoliposomal irinotecan (nal-IRI; MM-398) +/- 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: Results from t	Annals of Oncology. 2016 Sep;27(Suppl. 4):Meeting Abstract B04.
2016-08	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma	Journal of Hepatology. 2016 Aug;65(2):296-304.
2016-07	Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer	Expert Opinion on Pharmacotherapy. 2016 Jul;17(10):1413-1420.
2016-06	Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study	Annals of Oncology. 2016 Jun;27(Suppl. 2):ii84.
2016-06	Effects of nal-IRI (MM-398) +/- 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine	Annals of Oncology. 2016 Jun;27(Suppl. 2):119.
2016-06	Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2016 Jun;27(Suppl. 2):110.
2016-05-14	Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply	Lancet. 2016 May 14-20;387(10032):1997.
2016-05-03	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer	Scientific Reports. 2016 May 3;6:Article number 25369.
2016-05	Overexpression of regulator of G protein signaling 11 promotes cell migration and associates with advanced stages and aggressiveness of lung adenocarcinoma	Oncotarget. 2016 May;7(21):31122-31136.
2016-05	Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine	Journal of Clinical Oncology. 2016 May;34(15, Suppl.):Meeting Abstract 4126.
2016-05	Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15740.
2016-05	Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number 4017.
2016-05	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e15732.
2016-05	Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma	Journal of Clinical Oncology. 2016 May;34(15, Suppl. S):Abstract number e19024.
2016-03	miR-520h is crucial for DAPK2 regulation and breast cancer progression	Oncogene. 2016 Mar 3;35(9):1134-1142.
2016-03	Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer	Oncogene. 2016 May;35(12):1517-1528.
2016-02	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial	Lancet. 2016 Feb;387(10018):545-557.

顯示項目251-275 / 510. (共21頁) << < 6 7 8 9 10 11 12 13 14 15 > >> 每頁顯示[10|25|50]項目